Stimulation of Osteoclast Formation by Oncostatin M and the Role of WNT16 as a Negative Feedback Regulator

Karsenty, 2009, Genetic Control of Bone Formation, Annu. Rev. Cell Dev. Biol., 25, 629, 10.1146/annurev.cellbio.042308.113308

Buenzli, 2015, Quantifying the osteocyte network in the human skeleton, Bone, 75, 144, 10.1016/j.bone.2015.02.016

Dallas, 2013, The Osteocyte: An Endocrine Cell … and More, Endocr. Rev., 34, 658, 10.1210/er.2012-1026

Nakashima, 2011, Evidence for osteocyte regulation of bone homeostasis through RANKL expression, Nat. Med., 17, 1231, 10.1038/nm.2452

Xiong, 2011, Matrix-embedded cells control osteoclast formation, Nat. Med., 17, 1235, 10.1038/nm.2448

Nakashima, 2012, New insights into osteoclastogenic signaling mechanisms, Trends Endocrinol. Metab., 23, 582, 10.1016/j.tem.2012.05.005

Souza, 2013, The role of cytokines in inflammatory bone loss, Immunol. Investig., 42, 555, 10.3109/08820139.2013.822766

McDonald, 2021, Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption, Cell, 184, 1330, 10.1016/j.cell.2021.02.002

Delaisse, 2021, Osteoclast formation at the bone marrow/bone surface interface: Importance of structural elements, matrix, and intercellular communication, Semin. Cell Dev. Biol., 112, 8, 10.1016/j.semcdb.2020.05.016

Sims, 2020, Osteoclasts Provide Coupling Signals to Osteoblast Lineage Cells Through Multiple Mechanisms, Annu. Rev. Physiol., 82, 507, 10.1146/annurev-physiol-021119-034425

Khosla, 2018, Regulation of Bone Metabolism by Sex Steroids, Cold Spring Harb. Perspect. Med., 8, a031211, 10.1101/cshperspect.a031211

Zaidi, M. (2020). Role of Interleukins on Physiological and Pathological Bone Resorption and Bone Formation: Effects by Cytokines in The IL-6 and IL-10 Families. Encyclopedia of Bone Biology, Academic Press.

Sims, 2021, Influences of the IL-6 cytokine family on bone structure and function, Cytokine, 146, 155655, 10.1016/j.cyto.2021.155655

Henning, 2021, WNT16 is Robustly Increased by Oncostatin M in Mouse Calvarial Osteoblasts and Acts as a Negative Feedback Regulator of Osteoclast Formation Induced by Oncostatin M, J. Inflamm. Res., 14, 4723, 10.2147/JIR.S323435

Yoshida, 1990, The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene, Nature, 345, 442, 10.1038/345442a0

Bartocci, 1990, Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse, Proc. Natl. Acad. Sci. USA, 87, 4828, 10.1073/pnas.87.12.4828

Dai, 2002, Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects, Blood, 99, 111, 10.1182/blood.V99.1.111

Lin, 2008, Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome, Science, 320, 807, 10.1126/science.1154370

Chen, Z., Buki, K., Vääräniemi, J., Gu, G., and Väänänen, H.K. (2011). The Critical Role of IL-34 in Osteoclastogenesis. PLoS ONE, 6.

Martin, 2015, RANKL/OPG: Critical role in bone physiology, Rev. Endocr. Metab. Disord., 16, 131, 10.1007/s11154-014-9308-6

Simonet, 1997, Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3

Kong, 1999, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 315, 10.1038/16852

Dougall, 1999, RANK is essential for osteoclast and lymph node development, Genes Dev., 13, 2412, 10.1101/gad.13.18.2412

Tsukasaki, 2020, OPG Production Matters Where It Happened, Cell Rep., 32, 108124, 10.1016/j.celrep.2020.108124

Cawley, 2020, Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption, Cell Rep., 32, 108052, 10.1016/j.celrep.2020.108052

Tsukasaki, 2019, Osteoimmunology: Evolving concepts in bone–immune interactions in health and disease, Nat. Rev. Immunol., 19, 626, 10.1038/s41577-019-0178-8

Anderson, 1997, A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, 390, 175, 10.1038/36593

Wong, 1997, TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells, J. Biol. Chem., 272, 25190, 10.1074/jbc.272.40.25190

Okamoto, 2017, Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems, Physiol. Rev., 97, 1295, 10.1152/physrev.00036.2016

Takayanagi, 2002, Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts, Dev. Cell, 3, 889, 10.1016/S1534-5807(02)00369-6

Nishikawa, 2010, Blimp1-mediated repression of negative regulators is required for osteoclast differentiation, Proc. Natl. Acad. Sci. USA, 107, 3117, 10.1073/pnas.0912779107

Danks, 2016, RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation, Ann. Rheum. Dis., 75, 1187, 10.1136/annrheumdis-2014-207137

Komatsu, 2021, Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis, J. Clin. Investig., 131, e143060, 10.1172/JCI143060

Tsukasaki, 2018, Host defense against oral microbiota by bone-damaging T cells, Nat. Commun., 9, 1, 10.1038/s41467-018-03147-6

Zarling, 1986, Oncostatin M: A growth regulator produced by differentiated histiocytic lymphoma cells, Proc. Natl. Acad. Sci. USA, 83, 9739, 10.1073/pnas.83.24.9739

Koskela, 1997, Serum oncostatin M in multiple myeloma: Association with prognostic factors, Br. J. Haematol., 96, 158, 10.1046/j.1365-2141.1997.8522478.x

Gurluler, 2014, Oncostatin-M as a novel biomarker in colon cancer patients and its association with clinicopathologic variables, Eur. Rev. Med. Pharmacol. Sci., 18, 2042

Torres, 2014, Serum Cytokine Profile in Patients with Pancreatic Cancer, Pancreas, 43, 1042, 10.1097/MPA.0000000000000155

West, 2017, Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease, Nat. Med., 23, 579, 10.1038/nm.4307

Arunachalam, 2020, Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans, Science, 369, 1210, 10.1126/science.abc6261

Cross, 2004, Secretion of oncostatin M by neutrophils in rheumatoid arthritis, Arthritis Care Res., 50, 1430, 10.1002/art.20166

Pradeep, 2009, Serum levels of oncostatin M (a gp 130 cytokine): An inflammatory biomarker in periodontal disease, Biomarkers, 15, 277, 10.3109/13547500903573209

Grenier, 2001, Oncostatin M Production by Blood and Alveolar Neutrophils during Acute Lung Injury, Lab. Investig., 81, 133, 10.1038/labinvest.3780220

Suda, 2002, Oncostatin M Production by Human Dendritic Cells in Response to Bacterial Products, Cytokine, 17, 335, 10.1006/cyto.2002.1023

Brown, 1987, Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells, J. Immunol., 139, 2977, 10.4049/jimmunol.139.9.2977

Guihard, 2015, Oncostatin M, an Inflammatory Cytokine Produced by Macrophages, Supports Intramembranous Bone Healing in a Mouse Model of Tibia Injury, Am. J. Pathol., 185, 765, 10.1016/j.ajpath.2014.11.008

Walker, 2010, Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice, J. Clin. Investig., 120, 582, 10.1172/JCI40568

Auguste, 1997, Signaling of Type II Oncostatin M Receptor, J. Biol. Chem., 272, 15760, 10.1074/jbc.272.25.15760

Heinrich, 1998, Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway, Biochem. J., 334, 297, 10.1042/bj3340297

Rose, 1993, The Genes for Oncostatin M (OSM) and Leukemia Inhibitory Factor (LIF) Are Tightly Linked on Human Chromosome 22, Genomics, 17, 136, 10.1006/geno.1993.1294

Deller, 2000, Crystal structure and functional dissection of the cytostatic cytokine oncostatin M, Structure, 8, 863, 10.1016/S0969-2126(00)00176-3

Gearing, 1992, The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor, Science, 255, 1434, 10.1126/science.1542794

Mosley, 1996, Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation, J. Biol. Chem., 271, 32635, 10.1074/jbc.271.51.32635

Sporeno, 1994, Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors, J. Biol. Chem., 269, 10991, 10.1016/S0021-9258(19)78081-8

Heath, 2006, Oncostatin M (OSM) cytostasis of breast tumor cells: Characterization of an OSM receptor beta-specific kernel, Cancer Res., 66, 10891, 10.1158/0008-5472.CAN-06-1766

Bellido, 1996, Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells, J. Clin. Investig., 97, 431, 10.1172/JCI118432

Rodan, 1990, Leukemia Inhibitory Factor Binds with High Affinity to Preosteoblastic RCT-1 Cells and Potentiates the Retinoic Acid Induction of Alkaline Phosphatase, Endocrinology, 127, 1602, 10.1210/endo-127-4-1602

Palmqvist, 2002, IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae, J. Immunol., 169, 3353, 10.4049/jimmunol.169.6.3353

Allan, 1990, Osteoblasts display receptors for and responses to leukemia-inhibitory factor, J. Cell. Physiol., 145, 110, 10.1002/jcp.1041450116

Persson, 2019, Activation of Shc1 Allows Oncostatin M to Induce RANKL and Osteoclast Formation More Effectively Than Leukemia Inhibitory Factor, Front. Immunol., 10, 1164, 10.3389/fimmu.2019.01164

Singbrant, 2014, Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts, Cytokine, 68, 101, 10.1016/j.cyto.2014.04.001

Du, 2021, Cross-reactivity of two human IL-6 family cytokines OSM and LIF explored by protein-protein docking and molecular dynamics simulation, Biochim. Biophys. Acta Gen. Subj., 1865, 129907, 10.1016/j.bbagen.2021.129907

Huyton, 2007, An unusual cytokine: Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor, Proc. Natl. Acad. Sci. USA, 104, 12737, 10.1073/pnas.0705577104

Schindler, 2018, The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation, J. Biol. Chem., 293, 7017, 10.1074/jbc.RA118.001920

Sreenivasan, 2018, The AB loop of oncostatin M (OSM) determines species-specific signaling in humans and mice, J. Biol. Chem., 293, 20181, 10.1074/jbc.RA118.004375

Rose, 1991, Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6, Proc. Natl. Acad. Sci. USA, 88, 8641, 10.1073/pnas.88.19.8641

Robinson, 1994, The crystal structure and biological function of leukemia inhibitory factor: Implications for receptor binding, Cell, 77, 1101, 10.1016/0092-8674(94)90449-9

Tamura, 1993, Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6, Proc. Natl. Acad. Sci. USA, 90, 11924, 10.1073/pnas.90.24.11924

Gubrij, 1999, STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone, J. Biol. Chem., 274, 19301, 10.1074/jbc.274.27.19301

Richards, 2000, Stimulation of Osteoclast Differentiation In Vitro by Mouse Oncostatin M, Leukaemia Inhibitory Factor, Cardiotrophin-1 and Interleukin 6: Synergy with Dexamethasone, Cytokine, 12, 613, 10.1006/cyto.1999.0635

Blackwell, 2010, Prostaglandins in bone: Bad cop, good cop?, Trends Endocrinol. Metab., 21, 294, 10.1016/j.tem.2009.12.004

Walker, 2016, Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass, J. Biol. Chem., 291, 21703, 10.1074/jbc.M116.748483

Tabacco, 2019, Osteoanabolic and dual action drugs, Br. J. Clin. Pharmacol., 85, 1084, 10.1111/bcp.13766

Walker, 2012, Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo, J. Bone Miner. Res., 27, 902, 10.1002/jbmr.1506

Jay, 1996, Oncostatin-M: A new bone active cytokine that activates osteoblasts and inhibits bone resorption, Endocrinology, 137, 1151, 10.1210/endo.137.4.8625883

Sims, 2004, Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways, J. Clin. Investig., 113, 379, 10.1172/JCI19872

Itoh, 2006, A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation, Bone, 39, 505, 10.1016/j.bone.2006.02.074

Lindberg, 1998, Cloning and Characterization of a Specific Receptor for Mouse Oncostatin M, Mol. Cell. Biol., 18, 3357, 10.1128/MCB.18.6.3357

Hermanns, 2015, Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology, Cytokine Growth Factor Rev., 26, 545, 10.1016/j.cytogfr.2015.07.006

Hermanns, 1999, Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130, J. Immunol., 163, 6651, 10.4049/jimmunol.163.12.6651

Wegenka, 1994, Association of Transcription Factor APRF and Protein Kinase Jak1 with the Interleukin-6 Signal Transducer gp130, Science, 263, 89, 10.1126/science.8272872

Murakami, 1991, Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family, Proc. Natl. Acad. Sci. USA, 88, 11349, 10.1073/pnas.88.24.11349

Berger, 1994, Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11, Biochem. Biophys. Res. Commun., 202, 596, 10.1006/bbrc.1994.1970

Matsuda, 1994, Interleukin-6-Induced Tyrosine Phosphorylation of Multiple Proteins in Murine Hematopoietic Lineage Cells, Biochem. Biophys. Res. Commun., 200, 821, 10.1006/bbrc.1994.1525

Stahl, 1994, Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components, Science, 263, 92, 10.1126/science.8272873

Hintzen, 2008, Box 2 Region of the Oncostatin M Receptor Determines Specificity for Recruitment of Janus Kinases and STAT5 Activation, J. Biol. Chem., 283, 19465, 10.1074/jbc.M710157200

Guschin, 1995, A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6, EMBO J., 14, 1421, 10.1002/j.1460-2075.1995.tb07128.x

Haan, 2005, Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation, Cell. Signal., 17, 1542, 10.1016/j.cellsig.2005.03.010

Rodig, 1998, Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses, Cell, 93, 373, 10.1016/S0092-8674(00)81166-6

Takahashi, 2008, Leukemia Inhibitory Factor Regulates Trophoblast Giant Cell Differentiation via Janus Kinase 1-Signal Transducer and Activator of Transcription 3-Suppressor of Cytokine Signaling 3 Pathway, Mol. Endocrinol., 22, 1673, 10.1210/me.2008-0058

Gerhartz, 1996, Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation, J. Biol. Chem., 271, 12991, 10.1074/jbc.271.22.12991

Schmitz, 2000, The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction, J. Immunol., 164, 848, 10.4049/jimmunol.164.2.848

Heim, 1995, Contribution of STAT SH2 Groups to Specific Interferon Signaling by the Jak-STAT pathway, Science, 267, 1347, 10.1126/science.7871432

Hemmann, 1996, Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation, J. Biol. Chem., 271, 12999, 10.1074/jbc.271.22.12999

Fukada, 1996, Two Signals Are Necessary for Cell Proliferation Induced by a Cytokine Receptor gp130: Involvement of STAT3 in Anti-Apoptosis, Immunity, 5, 449, 10.1016/S1074-7613(00)80501-4

Fahmi, 2013, p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation, Cell. Signal., 25, 898, 10.1016/j.cellsig.2012.12.008

Oh, 1998, Activation of Phosphatidylinositol 3-Kinase through Glycoprotein 130 Induces Protein Kinase B and p70 S6 Kinase Phosphorylation in Cardiac Myocytes, J. Biol. Chem., 273, 9703, 10.1074/jbc.273.16.9703

Hermanns, 2000, Non-redundant signal transduction of interleukin-6-type cytokines. The adapter protein Shc is specifically recruited to rhe oncostatin M receptor, J. Biol. Chem., 275, 40742, 10.1074/jbc.M005408200

Kim, 2007, Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers, Mol. Endocrinol., 21, 197, 10.1210/me.2006-0315

Wang, 2000, Receptor Subunit-specific Action of Oncostatin M in Hepatic Cells and Its Modulation by Leukemia Inhibitory Factor, J. Biol. Chem., 275, 25273, 10.1074/jbc.M002296200

Ahmed, 2017, Insights into the Shc Family of Adaptor Proteins, J. Mol. Signal., 12, 2, 10.5334/1750-2187-12-2

Ravichandran, 2001, Signaling via Shc family adapter proteins, Oncogene, 20, 6322, 10.1038/sj.onc.1204776

Pelicci, 1992, A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction, Cell, 70, 93, 10.1016/0092-8674(92)90536-L

Ventura, 2002, The p66Shc Longevity Gene Is Silenced through Epigenetic Modifications of an Alternative Promoter, J. Biol. Chem., 277, 22370, 10.1074/jbc.M200280200

Rowan, 2003, Adenoviral Gene Transfer of Interleukin-1 in Combination with Oncostatin M Induces Significant Joint Damage in a Murine Model, Am. J. Pathol., 162, 1975, 10.1016/S0002-9440(10)64330-1

Hui, 2005, A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL, Arthritis Res. Ther., 7, R57, 10.1186/ar1460

Malik, 1995, Developmental abnormalities in mice transgenic for bovine oncostatin M, Mol. Cell. Biol., 15, 2349, 10.1128/MCB.15.5.2349

Bennink, 2002, Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand, Am. J. Pathol., 160, 1733, 10.1016/S0002-9440(10)61120-0

Nicolaidou, V., Wong, M.M., Redpath, A.N., Ersek, A., Baban, D.F., Williams, L.M., Cope, A.P., and Horwood, N.J. (2012). Monocytes Induce STAT3 Activation in Human Mesenchymal Stem Cells to Promote Osteoblast Formation. PLoS ONE, 7.

Estrada, 2012, Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture, Nat. Genet., 44, 491, 10.1038/ng.2249

Zheng, H.-F., Tobias, J.H., Duncan, E., Evans, D.M., Eriksson, J., Paternoster, L., Yerges-Armstrong, L.M., Lehtimäki, T., Bergström, U., and Kähönen, M. (2012). WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk. PLoS Genet., 8.

Henning, 2014, Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures, Nat. Med., 20, 1279, 10.1038/nm.3654

Wergedal, 2015, Role of WNT16 in the Regulation of Periosteal Bone Formation in Female Mice, Endocrinology, 156, 1023, 10.1210/en.2014-1702

Alam, 2016, Osteoblast-Specific Overexpression of Human WNT16 Increases Both Cortical and Trabecular Bone Mass and Structure in Mice, Endocrinology, 157, 722, 10.1210/en.2015-1281

Ohlsson, 2018, Inducible Wnt16 inactivation: WNT16 regulates cortical bone thickness in adult mice, J. Endocrinol., 237, 113, 10.1530/JOE-18-0020

Bloys, 1989, Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis, Biochem. Biophys. Res. Commun., 162, 1546, 10.1016/0006-291X(89)90851-6

Ishimi, 1990, IL-6 is produced by osteoblasts and induces bone resorption, J. Immunol., 145, 3297, 10.4049/jimmunol.145.10.3297

Sims, 2016, Cell-specific paracrine actions of IL-6 family cytokines from bone, marrow and muscle that control bone formation and resorption, Int. J. Biochem. Cell Biol., 79, 14, 10.1016/j.biocel.2016.08.003

Boulanger, 2003, Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex, Science, 300, 2101, 10.1126/science.1083901

Lacroix, 2015, Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex, J. Biol. Chem., 290, 26943, 10.1074/jbc.M115.682138

Kitamura, 1995, Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow, Am. J. Pathol., 147, 1682

Rucci, 2006, Impaired skeletal development in interleukin-6–transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system, Arthritis Care Res., 54, 3551, 10.1002/art.22175

Poli, 1994, Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion, EMBO J., 13, 1189, 10.1002/j.1460-2075.1994.tb06368.x

Jilka, 1992, Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6, Science, 257, 88, 10.1126/science.1621100

Lazzaro, 2018, IL-6 trans -signalling mediates trabecular, but not cortical, bone loss after ovariectomy, Bone, 112, 120, 10.1016/j.bone.2018.04.015

Girasole, 1994, Interleukin-11: A new cytokine critical for osteoclast development, J. Clin. Investig., 93, 1516, 10.1172/JCI117130

Ahlen, 2002, Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones, Bone, 31, 242, 10.1016/S8756-3282(02)00784-6

Horwood, 1998, Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells, Endocrinology, 139, 4743, 10.1210/endo.139.11.6433

Sims, 2005, Interleukin-11 Receptor Signaling Is Required for Normal Bone Remodeling, J. Bone Miner. Res., 20, 1093, 10.1359/JBMR.050209

Takeuchi, 2002, Interleukin-11 as a Stimulatory Factor for Bone Formation Prevents Bone Loss with Advancing Age in Mice, J. Biol. Chem., 277, 49011, 10.1074/jbc.M207804200

Shaughnessy, 2002, Neutralization of interleukin-11 activity decreases osteoclast formation and increases cancellous bone volume in ovariectomized mice, Cytokine, 20, 78, 10.1006/cyto.2002.1981

Walker, 2008, Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling, J. Bone Miner. Res., 23, 2025, 10.1359/jbmr.080706

McGregor, 2010, Ciliary Neurotrophic Factor Inhibits Bone Formation and Plays a Sex-Specific Role in Bone Growth and Remodeling, Calcif. Tissue Res., 86, 261, 10.1007/s00223-010-9337-4

Shukla, 2017, Interleukin 27 (IL-27) Alleviates Bone Loss in Estrogen-deficient Conditions by Induction of Early Growth Response-2 Gene, J. Biol. Chem., 292, 4686, 10.1074/jbc.M116.764779

Kamiya, 2007, Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: Inhibitory effects on osteoclast differentiation, J. Bone Miner. Metab., 25, 277, 10.1007/s00774-007-0766-8

Furukawa, 2009, IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos, J. Immunol., 183, 2397, 10.4049/jimmunol.0802091

Kalliolias, 2010, Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling, Arthritis Rheum., 62, 402, 10.1002/art.27200

Park, 2012, Interleukin-27 suppresses osteoclastogenesis via induction of interferon-gamma, Immunology, 137, 326, 10.1111/j.1365-2567.2012.03622.x

Li, 2019, Interleukin-27 prevents LPS-induced inflammatory osteolysis by inhibiting osteoclast formation and function, Am. J. Transl. Res., 11, 1154

Yago, 2018, IL-35 inhibits human osteoclastogenesis from monocytes induced by receptor-activator of NF-kappaB ligand, Cent. Eur. J. Immunol., 43, 148, 10.5114/ceji.2018.77384

Peng, 2018, Interleukin-35 Inhibits TNF-alpha-Induced Osteoclastogenesis and Promotes Apoptosis via Shifting the Activation from TNF Receptor-Associated Death Domain (TRADD)-TRAF2 to TRADD-Fas-Associated Death Domain by JAK1/STAT1, Front. Immunol., 9, 1417, 10.3389/fimmu.2018.01417

Lisignoli, 2000, Osteoblasts and stromal cells isolated from femora in rheumatoid arthritis (RA) and osteoarthritis (OA) patients express IL-11, leukaemia inhibitory factor and oncostatin M, Clin. Exp. Immunol., 119, 346, 10.1046/j.1365-2249.2000.01114.x

Torossian, 2017, Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications, JCI Insight, 2, 2, 10.1172/jci.insight.96034

Bolin, 2012, Oncostatin M Promotes Mammary Tumor Metastasis to Bone and Osteolytic Bone Degradation, Genes Cancer, 3, 117, 10.1177/1947601912458284

Omokehinde, 2022, gp130 Cytokines Activate Novel Signaling Pathways and Alter Bone Dissemination in ER+ Breast Cancer Cells, J. Bone Miner. Res., 7, 185